Immunovant Insiders Sold Shares Worth Over $2.9M

Christopher Van Tuyl, an officer serving as Chief Legal Officer, reported two direct sales of Immunovant common stock on June 26, 2026, at weighted average selling prices of $38.19 for 14,982 shares and $38.96 for 2,842 shares, for total reported sale proceeds of $682,886, and directly owned 180,597 shares following the reported transactions.

Stout Jay S, an officer serving as Chief Technology Officer, reported sales of Immunovant common stock on June 26, 2026, with filings showing weighted average prices of $38.18 for one block and $38.94 for a second block (each price a weighted average of multiple trades), for total reported sale proceeds of $1,532,309, and directly owned 211,685 shares following the reported transactions.

Gloria Melanie, an officer serving as Chief Operating Officer, reported sales of Immunovant common stock on June 26, 2026, at weighted average selling prices of $38.18 for one block and $38.95 for the other block, for total reported sale proceeds of $678,604, and directly owned 224,393 shares following the reported transactions.

This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.